Will TAVR Become the Predominant Method for Treating Severe Aortic Stenosis?

The results of the Placement of Aortic Transcatheter Valves (PARTNER) 2 trial that have now been published in the Journal represent another important piece of evidence by which to guide the contemporary management of symptomatic severe aortic stenosis.1 Who were the patients in this trial, and what does it teach us about their treatment?The Oxford English Dictionary defines the word “intermediate” as “holding the middle place . . . between two extremes.” The reader may assume that the patients in this trial form the middle ground in the risk spectrum between patients at low and high risk. The authors . . .